Shield Therapeutics plc (AIM:STX)
London · Delayed Price · Currency is GBP · Price in GBX 4.660
-0.236 (-4.82%)
Sep 11, 2026, 4:35 PM GMT
Shield Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 58.63 | 49.7 | 32.18 | 13.09 | 5.5 | 2.06 | |
Revenue Growth | 41.28% | 54.45% | 145.93% | 137.95% | 167.36% | -85.50% |
Cost of Revenue | 28.06 | 26.66 | 17.25 | 9.06 | 3.04 | 1.33 |
Gross Profit | 30.57 | 23.04 | 14.93 | 4.03 | 2.46 | 0.73 |
Selling, General & Admin | 32.92 | 31.59 | 36.01 | 37.96 | 33.65 | 27.28 |
Research & Development | 1.73 | 1.54 | 1.89 | 1.81 | 1.32 | 1.08 |
Other Operating Expenses | -0.04 | -0.04 | -0.1 | -4.41 | -0.86 | -0.15 |
Operating Expenses | 34.62 | 33.09 | 37.8 | 35.36 | 34.1 | 28.21 |
Operating Income | -4.05 | -10.05 | -22.87 | -31.33 | -31.65 | -27.48 |
Interest Expense | -6 | -7.42 | -3.87 | -1.02 | -0.4 | - |
Interest & Investment Income | - | 0.09 | 0.27 | 0.52 | 0.04 | 0.02 |
Currency Exchange Gain (Loss) | 0.06 | 0.06 | -0.08 | -0.54 | 0.85 | 0.52 |
Other Non Operating Income (Expenses) | -0 | -0 | - | -0 | -0.08 | -0.01 |
EBT Excluding Unusual Items | -10 | -17.32 | -26.56 | -32.38 | -31.24 | -26.96 |
Asset Writedown | - | - | - | - | -18.11 | - |
Other Unusual Items | 0.18 | 0.18 | - | - | - | - |
Pretax Income | -9.82 | -17.14 | -26.56 | -32.38 | -49.34 | -26.96 |
Income Tax Expense | 0.56 | 0.51 | 0.63 | 0.92 | 0.45 | -0.31 |
Earnings From Continuing Operations | -10.37 | -17.66 | -27.18 | -33.29 | -49.79 | -26.65 |
Net Income | -10.37 | -17.66 | -27.18 | -33.29 | -49.79 | -26.65 |
Net Income to Common | -10.37 | -17.66 | -27.18 | -33.29 | -49.79 | -26.65 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,061 | 1,047 | 783 | 723 | 233 | 204 |
Shares Outstanding (Diluted) | 1,061 | 1,047 | 783 | 723 | 233 | 204 |
Shares Change | 16.25% | 33.81% | 8.33% | 209.85% | 14.08% | 74.36% |
EPS (Basic) | -0.01 | -0.02 | -0.03 | -0.05 | -0.21 | -0.13 |
EPS (Diluted) | -0.01 | -0.02 | -0.03 | -0.05 | -0.21 | -0.13 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1.32 | -3.4 | -6.81 | -37.37 | -22.66 | -25.23 |
Free Cash Flow Per Share | 0.00 | -0.00 | -0.01 | -0.05 | -0.10 | -0.12 |
Gross Margin | 52.14% | 46.36% | 46.39% | 30.78% | 44.70% | 35.48% |
Operating Margin | -6.91% | -20.22% | -71.08% | -239.44% | -575.49% | -1336.01% |
Profit Margin | -17.69% | -35.52% | -84.47% | -254.44% | -905.42% | -1295.46% |
Free Cash Flow Margin | 2.25% | -6.85% | -21.15% | -285.56% | -411.98% | -1226.73% |
EBITDA | -4.43 | -9.82 | -22.38 | -31.08 | -29.67 | -25.39 |
EBITDA Margin | -7.56% | -19.76% | -69.56% | -237.51% | - | - |
D&A For EBITDA | -0.38 | 0.23 | 0.49 | 0.25 | 1.97 | 2.09 |
EBIT | -4.05 | -10.05 | -22.87 | -31.33 | -31.65 | -27.48 |
EBIT Margin | -6.91% | -20.22% | -71.08% | -239.44% | - | - |